BR9913457A - Neuroproteção - Google Patents
NeuroproteçãoInfo
- Publication number
- BR9913457A BR9913457A BR9913457-8A BR9913457A BR9913457A BR 9913457 A BR9913457 A BR 9913457A BR 9913457 A BR9913457 A BR 9913457A BR 9913457 A BR9913457 A BR 9913457A
- Authority
- BR
- Brazil
- Prior art keywords
- neuroprotection
- drugs
- growth hormone
- ligands
- primarily
- Prior art date
Links
- 230000004112 neuroprotection Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 102100020948 Growth hormone receptor Human genes 0.000 abstract 1
- 108010068542 Somatotropin Receptors Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Patente de Invenção: <B>"NEUROPROTEçãO"<D>. A invenção refere-se a neuroproteção e a medicamentos para uso na mesma. Neuroproteção é induzida por ativação de receptores de hormónio de crescimento neurais, usando primeiramente medicamentos compreendendo hormónio de crescimento, análogos de hormónio de crescimento ou ligandos que são funcionalmente equivalentes. Estes medicamentos também podem incluir um ou mais agentes neuroprotetores secundários.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ33171998 | 1998-09-03 | ||
PCT/NZ1999/000147 WO2000013650A2 (en) | 1998-09-03 | 1999-09-03 | Neuroprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913457A true BR9913457A (pt) | 2001-10-16 |
Family
ID=19926914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913457-8A BR9913457A (pt) | 1998-09-03 | 1999-09-03 | Neuroproteção |
Country Status (8)
Country | Link |
---|---|
US (1) | US7304029B1 (pt) |
EP (1) | EP1109572A4 (pt) |
JP (1) | JP2002524402A (pt) |
CN (1) | CN1261158C (pt) |
AU (1) | AU757907B2 (pt) |
BR (1) | BR9913457A (pt) |
CA (1) | CA2343214A1 (pt) |
WO (1) | WO2000013650A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7304029B1 (en) | 1998-09-03 | 2007-12-04 | Neuren Pharmaceuticals Ltd. | Neuroprotective effect of growth hormone |
US7112570B2 (en) | 2000-08-24 | 2006-09-26 | Neuren Pharmaceuticals, Ltd. | GPE analogs |
AU2001289160A1 (en) * | 2000-08-24 | 2002-03-04 | Neuronz Ltd. | Gpe analogs |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
AR036400A1 (es) * | 2001-08-30 | 2004-09-08 | Stem Cell Therapeutics Inc | Regulacion combinada de la produccion de celulas nerviosas. |
WO2003024472A2 (en) * | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof |
WO2003024471A2 (en) * | 2001-09-18 | 2003-03-27 | Stem Cell Therapeutics Inc. | Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
AU2002340465A1 (en) * | 2001-11-09 | 2003-05-19 | Neuronz Biosciences, Inc. | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
CA2492442A1 (en) | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
JP2006520371A (ja) * | 2003-03-14 | 2006-09-07 | メルク シャープ エンド ドーム リミテッド | 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法 |
CA2527039C (en) * | 2003-05-29 | 2013-07-09 | Theratechnologies Inc. | Grf analog compositions and their use |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
NZ544695A (en) * | 2003-07-29 | 2008-11-28 | Ares Trading Sa | Use of human growth hormone in multiple system atrophy |
DK1670444T3 (da) * | 2003-10-03 | 2011-08-22 | Veijlen N V | Anvendelse af IFG-1-serumniveau forhøjende indoleddikesyrederivater til fremstilling af en lægemiddelsammensætning til behandling af forskellige sygdomme |
JP2005239712A (ja) * | 2004-01-30 | 2005-09-08 | Kaken Pharmaceut Co Ltd | 神経突起伸展剤 |
AU2005211847B2 (en) | 2004-02-13 | 2011-02-24 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis |
KR20080074108A (ko) | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
EP2164509A1 (en) * | 2007-06-08 | 2010-03-24 | Massachusetts Institute of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
US20140357558A1 (en) * | 2011-06-24 | 2014-12-04 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of spinal muscular atrophy |
WO2017179225A1 (ja) * | 2016-04-13 | 2017-10-19 | 味の素株式会社 | 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4939124A (en) | 1988-01-26 | 1990-07-03 | Laboratorios Serono S.A. | Treatment and diagnosis of dementia |
US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
JP2820698B2 (ja) * | 1988-08-31 | 1998-11-05 | 第一製薬株式会社 | 脳機能改善剤 |
ATE156704T1 (de) * | 1989-12-05 | 1997-08-15 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
US5299836A (en) * | 1990-03-21 | 1994-04-05 | Woods Robert J | Floor waste fitting support |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
AU3129793A (en) * | 1991-11-08 | 1993-06-07 | General Hospital Corporation, The | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
EP0696205B1 (en) * | 1993-04-13 | 2002-01-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | Use of neuro-derived fetal cell lines for transplantation therapy |
SE9303068D0 (sv) | 1993-09-21 | 1993-09-21 | Kabi Pharmacia Ab | New use |
US5837234A (en) * | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
AU7719596A (en) * | 1995-11-07 | 1997-05-29 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
US6277618B1 (en) * | 1996-06-06 | 2001-08-21 | Roche Diagnostics Gmbh | Recombinant blood-coagulation proteases |
JP2001502323A (ja) * | 1996-10-16 | 2001-02-20 | リジェネロン ファーマシューティカルズ,インコーポレイテッド | 成長因子の送達を増強する方法 |
ES2146530B1 (es) * | 1997-12-26 | 2001-04-16 | Consejo Superior Investigacion | Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar. |
US7304029B1 (en) | 1998-09-03 | 2007-12-04 | Neuren Pharmaceuticals Ltd. | Neuroprotective effect of growth hormone |
AR036400A1 (es) | 2001-08-30 | 2004-09-08 | Stem Cell Therapeutics Inc | Regulacion combinada de la produccion de celulas nerviosas. |
WO2003024471A2 (en) | 2001-09-18 | 2003-03-27 | Stem Cell Therapeutics Inc. | Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
-
1999
- 1999-09-03 US US09/786,982 patent/US7304029B1/en not_active Expired - Fee Related
- 1999-09-03 WO PCT/NZ1999/000147 patent/WO2000013650A2/en active IP Right Grant
- 1999-09-03 EP EP99946457A patent/EP1109572A4/en not_active Withdrawn
- 1999-09-03 JP JP2000568459A patent/JP2002524402A/ja not_active Abandoned
- 1999-09-03 BR BR9913457-8A patent/BR9913457A/pt not_active IP Right Cessation
- 1999-09-03 AU AU58859/99A patent/AU757907B2/en not_active Ceased
- 1999-09-03 CN CNB998106135A patent/CN1261158C/zh not_active Expired - Fee Related
- 1999-09-03 CA CA002343214A patent/CA2343214A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU757907B2 (en) | 2003-03-13 |
EP1109572A2 (en) | 2001-06-27 |
WO2000013650A3 (en) | 2000-06-02 |
CN1316908A (zh) | 2001-10-10 |
WO2000013650A2 (en) | 2000-03-16 |
JP2002524402A (ja) | 2002-08-06 |
US7304029B1 (en) | 2007-12-04 |
EP1109572A4 (en) | 2004-11-24 |
AU5885999A (en) | 2000-03-27 |
CN1261158C (zh) | 2006-06-28 |
CA2343214A1 (en) | 2000-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913457A (pt) | Neuroproteção | |
BR9811249A (pt) | Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma | |
BR9612318A (pt) | "métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa" | |
BR9916576A (pt) | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 | |
BR9913602A (pt) | Transportador de catalisador de epoxidação, preparação e uso do mesmo | |
CO4940465A1 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona | |
BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
BR0213358A (pt) | Uso de flibanserina | |
BR9709062A (pt) | Composto, composição farmacêutica, e, uso de um composto. | |
ES2077948T3 (es) | Preparacion para el cuidado externo de la piel. | |
ES2182357T3 (es) | Nueva utilizacion de budesonide y formoterol. | |
GT199700009AA (es) | Terapia combinada para la osteoporosis | |
BR9813208A (pt) | Antagonista receptor de vitronectina | |
BR9813817A (pt) | Análogos de hemiasterlina | |
BR9903257A (pt) | Concentrado de suspensão aquosa contendo tiadiazurona e etefona | |
BR9811298A (pt) | Uso de um composto de vanádio fisiologicamente aceitável | |
BR9908427A (pt) | Composições farmacêuticas e uso das mesmas | |
BR0015540A (pt) | Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos | |
BG104038A (en) | Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing | |
CA2242224A1 (fr) | Microgranules a liberation prolongee contenant du diltiazem comme principe actif | |
BR9915879A (pt) | Antagonista de receptor de vitronectina | |
BR9812780A (pt) | 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio | |
BR9812404A (pt) | Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina | |
BR9806193A (pt) | Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm | |
DE59914183D1 (de) | Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |